As most people point out, its not going to get nailed. It was...

As most people point out, its not going to get nailed. It was trading around $3.70 equivalent on close. On Friday the US was trading around $4.80 equivalent. It had a lot to give back.

This remains, in my view, an incredibly appropriate treatment to the inflammatory story behind COIVD-19 deaths (not just ARDS I hope, as inflammatory incidents now started to been seen in children in UK studies alas). It not so much losing money on this I care about now. What I care about now is this treatment falling out of focus and a load of crappy drugs being instigated instead, which do little to address the underlying problem (unlike Remestemcel-L) and cause loads of bad side effects - you watch Gilead's Remedisivir cause renal issues....

In MSB for the long run (already was as of 2018 anyway) in the hope it really does get taken up, in a world where physicians are scratching their heads, trying all sorts of different approaches to a pandemic that is presenting in so many different ways (kidney, brain and heart failure as well as, and in tandem, with ARDS)